同济大学医学院，“青年百人”特聘研究员

同济大学附属上海市第四人民医院，特聘研究员（双聘）

Tongji University School of Medicine, Principal Investigator

Shanghai Fourth People’s Hospital affiliated to Tongji University School of Medicine, Principal Investigator

博士毕业于北京大学，2017-2021年在宾夕法尼亚大学从事博士后研究，2021年4月份加入同济大学医学院。入选上海市“海外高层次人才”，上海市浦江人才。擅长使用电生理、活细胞成像、脑片培养、小动物在体实验等技术研究神经退行性疾病致病蛋白（α-synuclein，Aβ和tau）的病理、生理功能。获得2020年ADDF基金会贡献奖，2020年Keystone 研讨会旅游奖，北京大学校长奖学金，华中科技大学优秀毕业生等荣誉。截止到2021年9月，以第一或通讯作者发表Neuron, Acta Neuropathologica, Science Signaling (封面文章), Journal of Neuroscience等国际权威SCI论文，累计25篇。课题组目前受到国家自然科学基金委、上海市科委、东西部合作重点项目等经费支持。

Dr Wu. obtained his PhD in Peking University (2011-2016), then he went to University of Pennsylvania to continue his postdoctoral training (2017-2021), and joined Tongji University School of Medicine on April 2021. His research interests focuses on the aggregation and spreading of α-synuclein and tau in Parkinson’s disease and Alzheimer’s disease, respectively, and the major experimental skills include electrophysiology, live-cell imaging, brain slice culture, and pre-formed fibrils (PFFs)-induced neurodegenerative disease models. Based on Dr. Wu’s talent work, he has been awarded ADDF fund travel award (2020), Keystone forum travel award (2020), Peking University Presidential Award (2015) and HUST Excellent Undergraduate (2011). All these academic achievements have been reflected in several high-profile publications, such as Neuron, Acta Neuropathologica, Science Signaling (Cover), Journal of Neuroscience, Nature Communications, PNAS, Molecular Neurodegeneration, and so on. His research has been supported by NSFC, Shanghai Science and Technology Committee.